Arrowhead Pharma announces press release on plozasiran Phase 3 SHASTA-3 and SHASTA-4 topline results

Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.

ARWR

0.00
  • Arrowhead released topline Phase 3 SHASTA-3 and SHASTA-4 results for plozasiran in severe hypertriglyceridemia, meeting the primary triglyceride endpoint.
  • Median triglycerides fell 79% and 81% at month 12 versus about 27% with placebo.
  • Pooled analysis showed a statistically significant drop in acute pancreatitis events; high-risk subgroup showed a 100% reduction versus placebo.
  • Arrowhead plans a U.S. sNDA for the severe hypertriglyceridemia indication before end-2026.
  • Full data set for ESC Congress Aug. 30, 2026; slides to post on Arrowhead’s Events and Presentations page.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607220730BIZWIRE_USPR_____20260722_BW499878) on July 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.